How Hospitals Move Innovation From Internal Pilot to External Adoption

A successful hospital pilot is not the same thing as commercialization. The first ten directory prototypes make that distinction visible without anyone needing to criticize a program.

Several systems describe pilots, proofs of concept, or clinical evaluation as a formal step. Fewer publish a complete account of what happens next: a license, a spinout, a paying customer outside the system, a joint venture, or an investment outcome.

Where pilots are part of the official model

Intermountain Ventures states that portfolio companies can use the health system for proofs of concept, clinical trials, and pilot programs. That is a documented pathway from external company to internal evaluation. It is not, by itself, evidence of external sales by Intermountain.

Cedars-Sinai Accelerator+ describes evaluation and product development inside the health system as part of the program. Current program materials also describe connections to other academic medical centers. Those are adoption steps the system has chosen to publish.

Where the published route is a license or a company

Mayo Clinic lists licensing, startup formation, equity investment, strategic collaborations, and mergers and acquisitions as official activities. Mass General Brigham Innovation lists licensing, company creation, and venture investing. Boston Children's TIDO describes license and option agreements when a company is formed.

Those routes can move an invention beyond the hospital that created it. The public pages do not always say which inventions took which route.

Where the published route is investment or a holdings structure

UPMC Enterprises describes investing in and forming companies. Northwell Holdings describes both external investment and the commercialization of internal innovations, including products, medical devices, joint ventures, and diversified revenue.

Again, the public fact is the existence of a route. The private question is which assets in the current portfolio belong on which route.

A practical distinction for hospital executives

Keep three events separate in any internal discussion:

1. Invention or idea. Something has been disclosed, designed, or piloted.
2. Internal adoption. The home system is using it.
3. External commercialization. Another organization has licensed it, bought it, invested in it, partnered around it, or become a customer.

The directory can document the first two from public sources more often than the third. That gap is not evidence of failure. It is a reason for a confidential review of the portfolio.

How does your innovation program compare? Request a confidential conversation about the commercial opportunities, market pathways, and capabilities within your hospital's innovation portfolio.